Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Murata Y;Murata Y; Catherman SC
  • Source:
    Vaccine [Vaccine] 2012 Aug 03; Vol. 30 (36), pp. 5382-8. Date of Electronic Publication: 2012 Jun 19.
  • Publication Type:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam, The Netherlands : Elsevier Science
      Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
    • Subject Terms:
    • Abstract:
      We examined the humoral immune response to the unglycosylated central region of the respiratory syncytial virus (RSV) attachment (G) protein in mice following intranasal challenge at day 0 (primary) and day 21 (secondary) with subtype A (A2 strain) or B (B1 strain) RSV preparations. Our serological screening reagents included bacterially derived glutathione S-transferase (GST) fusion proteins, each bearing a portion of the RSV G central core (CC; residues 151-190), proximal central core (PCC; residues 151-172), and the distal central core (DCC; residues 173-190) and purified RSV G proteins from subtype A and B viruses. Convalescent sera collected on day 21 following primary RSV infection bore robust IgG response primarily against the homosubtypic RSV G DCC with relatively modest antigen affinity/avidity as demonstrated by brief incubation with 6M urea. In contrast, sera collected on day 42 following secondary homosubtypic RSV infection bore IgG titers of higher magnitudes and antigen affinity/avidity against the homosubtypic RSV G CC, PCC, and/or the DCC regions and full-length RSV G protein but not against the heterosubtypic RSV G protein or recombinant CC subdomains. In contrast, heterosubtypic secondary RSV infection elicits a broad array of IgG responses with titers of varying magnitudes to homo- and heterosubtypic RSV G CC regions as well as to purified F, Ga, and Gb proteins with the notable exception of minimal response to the RSV G DCC domain associated with the secondary RSV challenge. Our results have implications for RSV G-based serological assays as well as prophylactic immunotherapy and RSV vaccine development.
      (Copyright © 2012 Elsevier Ltd. All rights reserved.)
    • References:
      J Gen Virol. 1989 Nov;70 ( Pt 11):2953-61. (PMID: 2479715)
      J Gen Virol. 1988 Feb;69 ( Pt 2):293-303. (PMID: 3339327)
      J Virol. 2008 Dec;82(24):12191-204. (PMID: 18842713)
      Curr Protoc Cell Biol. 2010 Mar;Chapter 26:Unit26.6. (PMID: 20235102)
      J Biol Chem. 2001 Oct 19;276(42):38988-94. (PMID: 11487583)
      J Med Virol. 1997 Apr;51(4):297-304. (PMID: 9093944)
      J Clin Microbiol. 1997 Jul;35(7):1656-60. (PMID: 9196168)
      J Med Virol. 2000 Apr;60(4):468-74. (PMID: 10686032)
      J Infect Dis. 1987 Jun;155(6):1198-204. (PMID: 3553346)
      J Immunol Methods. 1996 Jun 21;193(2):157-66. (PMID: 8699029)
      J Virol. 2003 Sep;77(18):9831-44. (PMID: 12941892)
      J Virol. 2010 Sep;84(18):9584-94. (PMID: 20592085)
      J Virol. 2010 Jan;84(2):1148-57. (PMID: 19864390)
      J Infect Dis. 2008 Oct 1;198(7):1007-15. (PMID: 18702606)
      Clin Vaccine Immunol. 2010 Apr;17(4):695-7. (PMID: 20164253)
      J Infect Dis. 2002 Jun 15;185(12):1780-5. (PMID: 12085325)
      Vaccine. 2010 Aug 31;28(38):6242-6. (PMID: 20655403)
      J Gen Virol. 1997 Oct;78 ( Pt 10):2411-8. (PMID: 9349459)
      J Virol. 1999 Sep;73(9):7099-107. (PMID: 10438795)
      J Infect Dis. 1991 Jul;164(1):15-21. (PMID: 2056202)
      Nat Med. 2009 Jan;15(1):34-41. (PMID: 19079256)
      J Virol. 2010 Jan;84(2):1110-23. (PMID: 19889768)
      Nat Med. 2003 Sep;9(9):1209-13. (PMID: 12925847)
      J Virol. 2009 Oct;83(20):10710-8. (PMID: 19656891)
      J Virol. 1999 Oct;73(10):8485-95. (PMID: 10482601)
      J Chromatogr B Biomed Sci Appl. 2000 Jan 14;737(1-2):97-106. (PMID: 10681046)
      J Immunol. 2006 Feb 1;176(3):1600-8. (PMID: 16424189)
      J Infect Dis. 1988 Apr;157(4):640-7. (PMID: 3346563)
      J Virol. 2007 Dec;81(24):13710-22. (PMID: 17928349)
      J Virol. 2004 Apr;78(7):3524-32. (PMID: 15016875)
      J Virol. 2010 Sep;84(18):9632-6. (PMID: 20592094)
      PLoS One. 2012;7(3):e34331. (PMID: 22479601)
      Vaccine. 1989 Dec;7(6):533-40. (PMID: 2692334)
      J Virol. 1998 Aug;72(8):6922-8. (PMID: 9658147)
      J Gen Virol. 1985 Mar;66 ( Pt 3):409-15. (PMID: 3838336)
      Virol J. 2009 Jun 18;6:81. (PMID: 19538743)
      Vaccine. 2009 Oct 23;27(45):6358-62. (PMID: 19840673)
      J Virol. 1988 Jul;62(7):2228-33. (PMID: 3373568)
      J Gen Virol. 1987 Aug;68 ( Pt 8):2169-76. (PMID: 3302101)
      J Virol. 1983 Jul;47(1):171-7. (PMID: 6345804)
      Clin Diagn Lab Immunol. 2002 May;9(3):633-8. (PMID: 11986272)
      J Virol. 2008 Mar;82(5):2040-55. (PMID: 17928346)
      J Med Virol. 1996 Mar;48(3):253-61. (PMID: 8801286)
      N Engl J Med. 2009 Feb 5;360(6):588-98. (PMID: 19196675)
      Future Microbiol. 2009 Apr;4(3):279-97. (PMID: 19327115)
      Virology. 1996 Jul 15;221(2):301-9. (PMID: 8661440)
      J Virol. 1998 Apr;72(4):2871-80. (PMID: 9525607)
    • Grant Information:
      R21 AI076781 United States AI NIAID NIH HHS; R56 AI091731 United States AI NIAID NIH HHS
    • Accession Number:
      0 (Antibodies, Viral)
      0 (Viral Envelope Proteins)
    • Publication Date:
      Date Created: 20120626 Date Completed: 20121221 Latest Revision: 20211021
    • Publication Date:
      20221213
    • Accession Number:
      PMC3401318
    • Accession Number:
      10.1016/j.vaccine.2012.06.016
    • Accession Number:
      22728222